argenx SE (LTS:0QW0)
€ 881.2 +15.6 (+1.8%) Market Cap: 54.43 Bil Enterprise Value: 49.99 Bil PE Ratio: 39.25 PB Ratio: 7.58 GF Score: 73/100

argenx SE Business Update Transcript

Aug 17, 2026 / 12:30PM GMT
Release Date Price: €854.5 (+16.97%)
Operator

Good morning. My name is Leila, and I will be your conference operator today. I would like to welcome everyone to the call. (Operator Instructions)

I'd like to introduce Beth DelGiacco, Vice President of Corporate Affairs. You may now begin your call.

Beth DelGiacco
argenx SE - Vice President, Corporate Affairs

Thanks, Leila, and welcome to everyone on the call.

Earlier today, we issued a press release summarizing positive top-line results from the Phase 3 ALKIVIA study of VYVGART Hytrulo in autoimmune myositis. The press release and the presentation for today's webcast are available on our website.

Before we begin on slide 2, I'd like to remind you that forward-looking statements may be presented during this call. These may include statements about our future expectations, clinical developments, regulatory timelines, the potential success of our product candidates, financial projections, and upcoming milestones. Actual results may differ materially from those indicated by these statements. argenx is not under any obligation to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot